Apple Inc. v. Gesture Technology Partners, LLC, Appeal Nos. 2023-1475, -1533 (Fed. Cir. Mar. 4, 2025)
Our Case of the Week is a high-stakes appeal from an inter partes review concerning a patent titled “Camera Based...more
3/11/2025
/ Appeals ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Remand ,
Technology ,
USPTO ,
Vacated
Mirror Worlds Technologies, LLC v. Meta Platforms, Inc., Appeal Nos. 2022-1600, -1709 (Fed. Cir. Dec. 4, 2024)
In this appeal from the United States District Court for the Southern District of New York, the Federal...more
12/10/2024
/ Appeals ,
Cross-Appeals ,
Doctrine of Equivalents ,
En Banc Review ,
Generic Drugs ,
Inter Partes Review (IPR) Proceeding ,
Noninfringement ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry ,
Summary Judgment ,
Technology
Yita LLC v. MacNeil IP LLC, Appeal Nos. 2022-1373, -1374 (Fed. Cir. June 6, 2023)
In appeals from two inter partes reviews before the Patent Trial and Appeal Board (the Board) on related patents, the Federal Circuit...more
6/12/2023
/ Appeals ,
Claim Construction ,
Design Patent ,
Inter Partes Review (IPR) Proceeding ,
Inventions ,
Inventors ,
Nonobvious ,
Obviousness ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents
Sanofi-Aventis Deutschland GmbH v. Mylan Pharmaceuticals Inc., Appeal No. 2021-1981 (Fed. Cir. May 9, 2023)
In our Case of the Week, the Court of Appeals for the Federal Circuit considered the “analogous art” inquiry in...more
5/16/2023
/ Appeals ,
Attorney's Fees ,
Design Patent ,
Inequitable Conduct ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Prior Art
Sequoia Technology, LLC v. Dell, Inc., Appeal Nos. 2021-2263, -2264, -2265, -2266 (Fed. Cir. April 12, 2023)
In an appeal from a stipulated judgment of noninfringement and invalidity following an adverse claim construction...more
4/18/2023
/ Anticipation ,
Appeals ,
Attorney's Fees ,
Claim Construction ,
Dismissal With Prejudice ,
Inter Partes Review (IPR) Proceeding ,
Noninfringement ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patent-in-Suit ,
Patents ,
Prior Art ,
Remand ,
Reversal ,
Section 101
American National Manufacturing Inc. v. Sleep Number Corporation, Appeal Nos. 2021-1321, -1323, -1379, -1382 (Fed. Cir. Nov. 14, 2022) -
In an appeal from inter partes review proceedings before the Patent Trial and Appeal...more
In re: Volkswagen Group of America, Inc. and In re: Hyundai Motor America, Appeal Nos. 2022-108, -109 (Fed. Cir. Mar. 9, 2022) -
In the most recent of multiple mandamus rulings issued by the Federal Circuit in relation to...more
3/15/2022
/ Appeals ,
Claim Construction ,
Dismissals ,
Improper Venue ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Vacated ,
Venue ,
Writ of Mandamus ,
Written Descriptions
Adapt Pharma Operations Limited v. Teva Pharmaceuticals USA, Inc., Appeal No. 2020-2106 (Fed. Cir. Feb. 10, 2022) -
In our Case of the Week, the Court of Appeals for the Federal Circuit, in both the majority opinion and...more
2/15/2022
/ Appeals ,
En Banc Review ,
Inter Partes Review (IPR) Proceeding ,
IP License ,
Motion To Seal ,
Obviousness ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Preliminary Injunctions ,
Prior Art ,
Remand ,
Third-Party ,
Vacated
AstraZeneca AB v. Mylan Pharmaceuticals Inc., Appeal No. 2021-1729 (Fed. Cir. Dec. 8, 2021) -
Our Case of the Week again focuses on numerical values in claims. Last week we addressed a case involving whether there was...more
Teva Pharms. Int’l GmbH v. Eli Lilly and Co., Appeal Nos. 2020-1747, -1748, -1750 (Fed. Cir. Aug. 16, 2021) -
Eli Lilly and Co. v. Teva Pharms. Int’l GmbH, Appeal Nos. 2020-1876, -1877, -1878 (Fed. Cir. Aug. 16, 2021)...more